Amedisys, Inc.

Amedisys, Inc.

AMED
Amedisys, Inc.US flagNASDAQ Global Select
100.99
USD
+0.01
- -
3.32BMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
48.19
39.98
37.29
38.78
42.75
44.84
50.7
60.84
63.62
67.83
68.37
68.6
71.77
73.28
Basic EPS, GAAP
-2.8
-3.08
0.4
-0.09
1.12
0.9
3.64
3.95
5.64
6.4
3.65
-0.3
1.32
2.61
Free Cash Flow per Basic Share
0.71
1.94
-2.4
2.62
1.4
2.82
6.62
6.04
8.71
5.58
3.88
3.82
6.55
7.14
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.62
-2.48
-2
-2.05
-0.92
0.01
3.65
7.67
13.21
19.58
23.3
22.94
24.18
26.85
Tangible Book Value per Share
6.61
4.06
4.92
3.17
3.78
4.46
3.32
-2.54
-6.02
-10.14
-8.67
-6.98
-3.52
-0.56
Basic Weighted Avg Shares
30
31
32
33
33
34
33
32
33
33
33
33
33
33
Sales/Revenue/Turnover
1,441
1,249
1,205
1,281
1,419
1,511
1,663
1,956
2,072
2,214
2,223
2,236
2,348
2,402
Operating Margin (%)
3.7
0.36
2.25
5.32
4.35
7.18
9.33
9.15
10.79
11.38
8.27
8.63
8.92
9.41
Depreciation Expense
40
37
28
20
20
17
13
54
68
71
71
58
60
62
Net Income, GAAP
-84
-96
13
-3
37
30
119
127
184
209
119
-10
43
86
Effective Tax Rate (%)
- -
- -
36.57
- -
38.88
62.03
24.44
24.94
12.16
25
26.55
127.6
55.74
45.16
Profit Margin (%)
-5.8
-7.7
1.06
-0.24
2.63
2
7.18
6.49
8.86
9.44
5.34
-0.44
1.84
3.56
Working Capital
1
-107
-27
- -
34
96
2
24
-94
-18
33
23
118
174
LT Debt
67
33
104
92
88
78
6
288
266
501
489
425
395
387
Total Equity
454
372
398
410
461
516
483
642
811
976
1,107
1,120
1,180
1,275
Return on Invested Capital (%)
- -
- -
3.77
- -
7.34
7.35
21.74
18.35
18.76
14.28
8.52
-3.28
5.71
7.34
Return on Capital (%)
- -
- -
144.46
- -
85.04
41.09
113.31
38.96
29.22
21.86
10.53
-1.3
4.79
7.75
Return on Common Equity (%)
-138.29
- -
- -
- -
- -
- -
199.2
69.31
54.29
39.11
16.98
-1.29
5.62
10.22

Capital Structure

FRC

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
64
63
64
LT Borrowings
339
333
326
LT Finance Leases
56
56
60
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
33
33
Market Capitalization
2,970
3,034
3,226

Working Capital

FRC

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
632
634
662
Cash, Cash Equivalents & STI
303
285
337
Accounts Receivable, Net
296
320
296
Inventories
- -
- -
- -
Total Current Liabilities
514
492
488
Payables & Accruals
303
323
319
ST Debt
64
63
64
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.06%
13.34%
5.37%
Free Cash Flow
1.49%
10.09%
72.16%
Net Income, GAAP
-181.2%
-127.28%
-543.53%
Sales/Revenue/Turnover
7.01%
3.76%
5.01%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
556
553
556
571
2,236
2024
571
591
588
598
2,348
2025
595
622
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.78
-2.46
0.8
0.59
-0.3
2024
0.44
0.99
0.52
-0.62
1.32
2025
1.86
0.85
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Richard M. Ashworth
Full Time Employees
19,000
Sector
Healthcare
Industry
Medical - Care Facilities
Address
3854 American Way Baton Rouge LA United States of America 70816
IPO Date
Aug 17, 1994
Business
Amedisys, Inc. (AMED) operates as a leading provider of home-based healthcare services in the United States, delivering home health, hospice, palliative, and high-acuity care to patients nationwide. Founded in 1982 and headquartered in Baton Rouge, Louisiana, with an additional executive office in Nashville, Tennessee, the company offers skilled nursing; physical, occupational, and speech therapy; medical social work; home health aides; personal care services including companion care, homemaker services, and live-in care; hospice care encompassing pain and symptom management, emotional and spiritual support, and bereavement counseling; palliative care for symptom relief and quality-of-life enhancement; and high-acuity care through its Contessa Health division featuring IV therapy, wound care, remote patient monitoring, and telehealth for hospital-level needs at home. Amedisys serves patients recovering from illness or surgery, those with chronic conditions, and individuals with life-limiting illnesses, primarily through Medicare reimbursement, across a network of care centers that supports over 499,000 patients annually with approximately 19,000 employees. As of August 14, 2025, Amedisys functions as a subsidiary of Optum, Inc., following Optum's $3.3 billion acquisition completed after regulatory settlement requiring divestiture of 164 locations; certain divested home health and hospice assets, generating $187 million in revenue from 54 locations, were acquired by Pennant Group in late 2025, while others went to BrightSpring, marking a major restructuring to facilitate the UnitedHealth Group integration.

Company News

APIChat
  • Joel Greenblatt's Strategic Moves: A Closer Look at SPDR S&P 500 ETF Trust

  • Twilio Set to Join S&P MidCap 400

  • Amedisys: Thoughts On UnitedHealth Merger, Plus Underlying Factors

  • Amedisys (AMED) is a Top-Ranked Value Stock: Should You Buy?

  • Amedisys (AMED) Q2 Revenue Tops 5%

  • Here's What Key Metrics Tell Us About Amedisys (AMED) Q2 Earnings

  • Amedisys (AMED) Beats Q2 Earnings and Revenue Estimates

  • Amedisys Reports Second Quarter 2025 Financial Results

  • Here's Why You Should Retain AMED Stock in Your Portfolio for Now

  • AMED or CHE: Which Is the Better Value Stock Right Now?

  • Are Medical Stocks Lagging Amedisys (AMED) This Year?

  • AMED Stock Trades Flat Despite Q1 Earnings Beat, Margins Rise

  • Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics

  • Amedisys (AMED) Tops Q1 Earnings Estimates

  • Amedisys Reports First Quarter 2025 Financial Results

  • Amedisys (AMED) Earnings Expected to Grow: Should You Buy?

  • Why Is Amedisys (AMED) Up 1.3% Since Last Earnings Report?

  • Here's Why You Should Retain AMED Stock in Your Portfolio Now

  • AMED Q4 Earnings and Revenues Miss, Margins Dip, Stock Rises

  • Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say